The two organizations will seek to engage stakeholders worldwide in order to increase demand for and access to HCV diagnostics.
Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.
The firm said that the test provides results of HBV status in 15 minutes with high analytical sensitivity, and that testing can be completed while the patient is present.
Deck: Increases in denials from insurers, uncollectible patient balances, and reimbursement pressures negatively affected company revenues.
The test measures hepatitis B viral DNA and is intended to be used to assess prognosis and response to antiviral therapies.
The assay is designed to quantitate HBV DNA in serum or plasma to assist in the treatment of chronic HBV-infected patients receiving antiviral therapy.
The lab analytics service provides insurers with guidance aimed at helping them achieve improvements in quality performance metrics.
The company said its molecular collection systems products saw the highest revenue growth during the quarter as product revenues rose 6 percent overall.
Qiagen's partnership and merger agreement with NeuMoDx may help it compete with high-volume molecular testing vendors such as Abbott, Hologic, and Roche.
With the patented Dual Path Platform as its foundation, Chembio is expanding its commercial and manufacturing capabilities, its CEO said.